DiaMedica Therapeutics (DMAC) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entera Bio (ENTX) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 32.8% versus a gain of 16.5%. Over five years, DMAC leads with a +94.9% price change compared with -44.5% for ENTX. Entera Bio is the larger company by market cap ($432.0 million vs $418.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | ENTX |
|---|---|---|
| Share price | $7.77 | $2.49 |
| Market cap | $418.73M | $431.98M |
| 1-day change | -2.82% | -1.00% |
| YTD return | +0.38% | +29.38% |
| 1-year return | +16.47% | +32.80% |
| 5-year return | +94.88% | -44.47% |
| EPS (TTM) | $-0.72 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.42 | $4.20 |
| 52-week low | $5.25 | $0.91 |
| Distance from 52-week high | -25.48% | -40.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.61% | +292.35% |
| Average volume | 176.44K | 1.82M |
| Shares outstanding | 53.93M | 173.83M |
| Employees | 35 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed DMAC by 16.3 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
DMAC vs ENTX FAQ
Which is bigger, DiaMedica Therapeutics or Entera Bio?
Entera Bio (ENTX) is larger, with a market capitalization of $431.98M compared with $418.73M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or ENTX?
ENTX returned +32.80% over the past 12 months, compared with +16.47% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Entera Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for DiaMedica Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Entera Bio.